Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EQGNV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MYK-3
|
|||||
| Synonyms |
MYK 3
Click to Show/Hide
|
|||||
| Organization |
Shanghai Miracogen Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Rectal cancer [ICD11:2B92]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.1
|
|||||
| Structure |
|
|||||
| Antibody Name |
BA03
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 35) | Moderate EGFR expression (EGFR ++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 0.3 mg/kg, i.v., q4d*4 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | LoVo CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 46.00% (Day 18) | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., q4d*4 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | HT-29 CDX model | ||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 54.00% (Day 18) | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., q4d*4 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | HT-29 CDX model | ||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.70% (Day 35) | Moderate EGFR expression (EGFR ++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., q4d*4 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | LoVo CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.60% (Day 35) | Moderate EGFR expression (EGFR ++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., q4d*4 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | LoVo CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 5.10 ng/mL | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Colorectal carcinoma | DiFi cells | CVCL_6895 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 9.80 ng/mL | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Colorectal carcinoma | DiFi cells | CVCL_6895 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 611.00 ng/mL | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.20 ug/mL | Moderate EGFR expression (EGFR ++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 5.30 ug/mL | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 28.30 ug/mL | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.